This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of Atorvastatin Treatment on Carotid Plaque.

This study has been terminated.
(The study was terminated on June 22, 2007 for inability to enroll patients within an appropriate timeframe. There were no efficacy/safety concerns.)
Information provided by:
Pfizer Identifier:
First received: June 20, 2006
Last updated: June 13, 2008
Last verified: June 2008
The purpose of the study is to evaluate the effect of 18 months treatment with atorvastatin 80mg or atorvastatin 10mg on the carotid vessel plaque morphology, in particular, the effect on evident necrotic lipid rich core of the plaque in patients.

Condition Intervention Phase
Cardiovascular Diseases Drug: Atorvastatin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized Clinical Trial Of Atorvastatin 10 Mg And 80 Mg In The Reversal Of Or Stabilization Of Carotid Atheroma Lipid Pool

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Change in lipid pool volume from baseline to 18 months in response to atorvastatin 80mg.
  • Comparison of effect of atorvastatin 80mg versus 10mg

Secondary Outcome Measures:
  • Correlation of MRI measure of carotid morphology with cIMT measured by B-mode US.
  • Correlation of MRI measure of carotid morphology with DS-CT measure of coronary morphology.
  • Correlation of biomarkers to carotid changes.

Estimated Enrollment: 160
Study Start Date: January 2007
Study Completion Date: August 2007

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects with measurable carotid plaque with lipid and are eligible for statin therapy.

Exclusion Criteria:

  • Subjects at higher risk for cardiovascular disease with a screen LDL-cholesterol greater than 120 mg/dL,
  • Subjects currently on high dose statin, and
  • Subjects with contraindications for MRI or statin therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00343655

United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information: Identifier: NCT00343655     History of Changes
Other Study ID Numbers: A2581152
Study First Received: June 20, 2006
Last Updated: June 13, 2008

Keywords provided by Pfizer:

Additional relevant MeSH terms:
Cardiovascular Diseases
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on August 16, 2017